ASCO GI 2023 Results From the TAPUR Study: Pertuzumab + Trastuzumab for Biliary Tract Cancer With ERBB2/3 Amplification, Overexpression, or Mutation

166 views
February 7, 2023
Comments 0
Login to view comments. Click here to Login